Spondyloarthritis & psoriatic arthritis
Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry
An erratum to this article was published (Arthritis Res Ther, 25 Oct 2023 ↗)
Authors' conclusion
Discontinuation of bDMARDs in patients who achieve remission is uncommon in routine clinical care. Smoking and positive ACPA in RA patients were associated with a lower probability of treatment discontinuation because of clinical remission.
Study context
- Population
- Adults with rheumatoid arthritis (RA), ankylosing spondylitis (AS) or psoriatic arthritis (PsA) receiving 1 or 2 bDMARDs, BIOBADASER registry, October 1999–April 2021
- Participants
- 3,366 adults
- Exposure
- RA vs AS vs PsA
- Outcome
- Discontinuation of bDMARDs because of remission (as defined by the attending clinician) and its predictors
Methodological detailsregistry-based (BIOBADASER), multivariable regression
- Registry-based (BIOBADASER)
- Multivariable regression
Main finding
As reported in the abstract
bDMARD discontinuation owing to remission
- Overall discontinuation owing to remission, 80 patients
- 2.4%
Observational data: associations, not effects.
Further findings
Predictors of bDMARD discontinuation owing to remission (multivariable regression)
| OR for discontinuation owing to remission (95% CI) | ||
|---|---|---|
| Disease duration | 0.95 (0.91–0.99) | |
| Concomitant classic DMARDs | 0.56 (0.34–0.92) | |
| Usage of previous bDMARD | 1.01 (1.01–1.02) | |
| Smoking statusAssociated with lower probability of discontinuation | 2.48 (1.21–5.08) | |
| 0.20.5125OR for discontinuation owing to remission (log scale) |
Predictor of bDMARD discontinuation owing to remission in RA (subgroup)
| OR for discontinuation owing to remission (95% CI) | ||
|---|---|---|
| Positive ACPAAssociated with lower probability of discontinuation | 0.11 (0.02–0.53) | |
| 0.050.21520OR for discontinuation owing to remission (log scale) |
- Predictors of bDMARD discontinuation owing to remission (multivariable regression): shorter disease duration associated with higher probability of discontinuation
- Predictors of bDMARD discontinuation owing to remission (multivariable regression): no concomitant use associated with higher probability of discontinuation
- Predictors of bDMARD discontinuation owing to remission (multivariable regression): shorter usage associated with higher probability of discontinuation
Original publication
Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry. Arthritis Res Ther. Published 22 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →